Belgium’s largest drugmaker UCB on Friday announced the successful closing of the sale, divestment and license of its mature ...

Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

It was only last October that UCB’s up-and-coming immunology powerhouse Bimzelx first crossed the FDA finish line in ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

CBC Group, Asia's largest healthcare asset management firm, has acquired UCB's neurology and allergy business in China in ...

This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...

Royalty Pharma’s founder and CEO, said in a statement. In 2016, Syndax gained exclusive rights to develop and commercialize axatilimab from UCB. Five years later, Incyte bought in to co-develop ...

UCB’s Bimzelx (bimekizumab-bkzx) has been approved by the US Food and Drug Administration (FDA) to treat active ...

UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free ...

CBC Group and Mubadala acquire UCB's mature neurology and allergy business in China for US$680 million. New company is named NeuroGen Pharma, led by an experienced management team with a strong track ...

DelveInsight's "Crohn’s Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth ...